Bio-Gene Technology Ltd (BGT) - Total Assets
Based on the latest financial reports, Bio-Gene Technology Ltd (BGT) holds total assets worth AU$1.47 Million AUD (≈ $1.04 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Bio-Gene Technology Ltd for net asset value and shareholders' equity analysis.
Bio-Gene Technology Ltd - Total Assets Trend (2014–2025)
This chart illustrates how Bio-Gene Technology Ltd's total assets have evolved over time, based on quarterly financial data.
Bio-Gene Technology Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Bio-Gene Technology Ltd's total assets of AU$1.47 Million consist of 91.7% current assets and 8.4% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 53.0% |
| Accounts Receivable | AU$472.42K | 22.0% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$13.35K | 0.6% |
| Intangible Assets | AU$166.24K | 7.7% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Bio-Gene Technology Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BGT stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bio-Gene Technology Ltd's current assets represent 91.7% of total assets in 2025, an increase from 34.9% in 2014.
- Cash Position: Cash and equivalents constituted 53.0% of total assets in 2025, up from 17.6% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 62.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 22.0% of total assets.
Bio-Gene Technology Ltd Competitors by Total Assets
Key competitors of Bio-Gene Technology Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Bio-Gene Technology Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.31 | 3.38 | 8.61 |
| Quick Ratio | 4.31 | 3.38 | 8.61 |
| Cash Ratio | 0.00 | 0.00 | 8.18 |
| Working Capital | AU$1.01 Million | AU$1.17 Million | AU$4.66 Million |
Bio-Gene Technology Ltd - Advanced Valuation Insights
This section examines the relationship between Bio-Gene Technology Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.63 |
| Latest Market Cap to Assets Ratio | 3.71 |
| Asset Growth Rate (YoY) | -32.0% |
| Total Assets | AU$2.15 Million |
| Market Capitalization | $7.99 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Bio-Gene Technology Ltd's assets at a significant premium (3.71x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Bio-Gene Technology Ltd's assets decreased by 32.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bio-Gene Technology Ltd (2014–2025)
The table below shows the annual total assets of Bio-Gene Technology Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$2.15 Million ≈ $1.52 Million |
-31.95% |
| 2024-06-30 | AU$3.16 Million ≈ $2.24 Million |
-17.62% |
| 2023-06-30 | AU$3.84 Million ≈ $2.71 Million |
-47.49% |
| 2022-06-30 | AU$7.30 Million ≈ $5.17 Million |
+46.04% |
| 2021-06-30 | AU$5.00 Million ≈ $3.54 Million |
-23.88% |
| 2020-06-30 | AU$6.57 Million ≈ $4.65 Million |
+18.09% |
| 2019-06-30 | AU$5.56 Million ≈ $3.94 Million |
-27.44% |
| 2018-06-30 | AU$7.67 Million ≈ $5.42 Million |
-18.83% |
| 2017-06-30 | AU$9.45 Million ≈ $6.68 Million |
+1002.99% |
| 2016-06-30 | AU$856.35K ≈ $605.92K |
+96.70% |
| 2015-06-30 | AU$435.36K ≈ $308.04K |
+49.62% |
| 2014-06-30 | AU$290.99K ≈ $205.89K |
-- |
About Bio-Gene Technology Ltd
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with Jame… Read more